Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 17;18(10):79.
doi: 10.1007/s11892-018-1041-1.

Adjuvant Pharmacotherapies to Insulin for the Treatment of Type 1 Diabetes


Adjuvant Pharmacotherapies to Insulin for the Treatment of Type 1 Diabetes

Mustafa Tosur et al. Curr Diab Rep. .


Purpose of review: Insulin therapy alone fails to achieve target glycemic control in the majority of individuals with type 1 diabetes (T1D), motivating the investigation of additive medications. This review focuses on the recent findings on the use of adjunctive pharmacotherapy in T1D.

Recent findings: Metformin and glucagon-like peptide-1 receptor agonists have been associated with weight reduction and decrease in daily insulin requirements without sustainable improvement in glycemic control. Sodium-glucose cotransporter (SGLT)-2 inhibitors, dual SGLT-1/2 inhibitors, and pramlintide have been shown to reduce hemoglobin A1c, induce weight loss, and lower insulin dose. The benefits of dipeptidyl peptidase-4 inhibitors, thiazolidinediones, and alpha glucosidase inhibitors appear to be more limited. Gastrointestinal symptoms and increased hypoglycemia are adverse effects of certain classes. Although not devoid of side effects, additive pharmacotherapies in T1D can improve glycemic control and lower body weight and insulin requirement. Longer studies are needed before consideration for widespread clinical care.

Keywords: Adjuvant therapy, metformin; GLP-1 receptor agonists; SGLT-1/2 inhibitors; SGLT-2 inhibitors; Type 1 diabetes.

Similar articles

See all similar articles

Cited by 1 article


    1. Diabet Med. 2008 Sep;25(9):1015-24 - PubMed
    1. Pediatr Diabetes. 2015 May;16(3):196-203 - PubMed
    1. Diabetes Care. 2005 Jul;28(7):1562-7 - PubMed
    1. Diabetes Care. 2015 Jan;38(1):140-9 - PubMed
    1. Diabetes Care. 2015 Jun;38(6):971-8 - PubMed

MeSH terms

LinkOut - more resources